Variables | 3-year PRS (95% CI) | Univariate | Multivariate | ||
---|---|---|---|---|---|
Recurrence group | HR (95% CI) | P-value | HR (95% CI) | P-value | |
Local recurrence | 66.83 (53.04, 84.22) | 1.0 (reference) | 1.0 (reference) | ||
Distant metastasis | 49.41 (44.16, 55.27) | 1.75 (0.97, 3.15) | 0.0618 | 1.19 (0.60, 2.38) | 0.6185 |
Simultaneous recurrence | 30.32 (21.10, 43.56) | 2.96 (1.56, 5.62) | 0.0009 | 2.17 (1.01, 4.64) | 0.0465 |
Recurrence time | |||||
Early recurrence | 44.59 (38.85, 51.19) | 1.0 (reference) | |||
Late recurrence | 53.28 (46.20, 61.45) | 0.78 (0.59, 1.02) | 0.0717 | ||
Recurrence site | |||||
Liver | 54.04 (45.46, 64.24) | 1.0 (reference) | |||
Lung | 50.05 (42.50, 58.95) | 1.12 (0.79, 1.61) | 0.5172 | ||
Peritoneum | 25.43 (14.76, 43.82) | 2.23 (1.38, 3.60) | 0.0011 | ||
Other individual organ | 46.26 (36.03, 59.40) | 1.25 (0.82, 1.91) | 0.2943 | ||
Two or more organs or sites | 34.84 (24.16, 50.24) | 1.71 (1.10, 2.66) | 0.0163 | ||
Local recurrence | 66.99 (53.23, 84.32) | 0.65 (0.35, 1.22) | 0.1829 | ||
Liver | |||||
No | 46.00 (40.68, 52.01) | 1.0 (reference) | |||
Yes | 54.04 (45.46, 64.24) | 0.80 (0.58, 1.09) | 0.1526 | ||
Lung | |||||
No | 47.03 (41.47, 53.34) | 1.0 (reference) | |||
Yes | 50.05 (42.50, 58.95) | 0.92 (0.70, 1.22) | 0.5704 | ||
Peritoneum | |||||
No | 49.89 (44.96, 55.36) | 1.0 (reference) | 1.0 (reference) | ||
Yes | 25.43 (14.76, 43.82) | 1.97 (1.30, 2.98) | 0.0015 | 1.75 (1.10, 2.79) | 0.0189 |
Other individual organ | |||||
No | 48.29 (43.20, 53.99) | 1.0 (reference) | |||
Yes | 46.26 (36.03, 59.40) | 1.06 (0.75, 1.50) | 0.7323 | ||
Two or more organs or sites | |||||
No | 49.68 (44.67, 55.26) | 1.0 (reference) | 1.0 (reference) | ||
Yes | 34.84 (24.16, 50.24) | 1.51 (1.04, 2.18) | 0.0296 | 1.59 (1.05, 2.43) | 0.0304 |
Local recurrence | |||||
No | 46.47 (41.59, 51.93) | 1.0 (reference) | 1.0 (reference) | ||
Yes | 66.99 (53.23, 84.32) | 0.53 (0.29, 0.94) | 0.0310 | 0.48 (0.22, 1.03) | 0.0582 |
Sex | |||||
Male | 46.60 (40.50, 53.62) | 1.0 (reference) | |||
Female | 49.51 (43.00, 57.00) | 0.92 (0.71, 1.19) | 0.5295 | ||
Surgical approach | |||||
OR | 46.87 (41.46, 52.98) | 1.0 (reference) | |||
LR | 50.83 (42.56, 60.72) | 0.89 (0.66, 1.20) | 0.4556 | ||
Primary site | |||||
Right colon | 41.69 (33.70, 51.57) | 1.0 (reference) | 1.0 (reference) | ||
Left colon | 55.91 (46.70, 66.95) | 0.66 (0.45, 0.98) | 0.0370 | 0.67 (0.44, 1.01) | 0.0538 |
Rectum | 48.02 (41.85, 55.10) | 0.84 (0.62, 1.13) | 0.2419 | 0.87 (0.62, 1.24) | 0.4475 |
Tumor differentiation | |||||
Well | 56.79 (38.27, 84.26) | 1.0 (reference) | |||
Moderate | 52.61 (46.24, 59.87) | 1.13 (0.55, 2.33) | 0.7300 | ||
Poor-undifferentiated | 41.62 (34.63, 50.03) | 1.55 (0.75, 3.19) | 0.2346 | ||
Mucinous type | |||||
No | 48.48 (43.62, 53.89) | 1.0 (reference) | |||
Yes | 38.25 (23.05, 63.47) | 1.33 (0.77, 2.28) | 0.3054 | ||
T stag | |||||
T0 | 70.85 (50.49, 99.41) | 1.0 (reference) | |||
T1 | 65.86 (53.18, 81.58) | 1.21 (0.40, 3.66) | 0.7313 | ||
T3 | 44.65 (39.55, 50.41) | 2.34 (0.87, 6.30) | 0.0921 | ||
T4 | 55.71 (39.35, 78.86) | 1.70 (0.54, 5.34) | 0.3646 | ||
N stag | |||||
N0 | 63.07 (56.29, 70.66) | 1.0 (reference) | 1.0 (reference) | ||
N1 | 44.06 (36.95, 52.53) | 1.78 (1.30, 2.43) | 0.0003 | 1.49 (1.04, 2.15) | 0.0315 |
N2 | 26.55 (21.13, 38.57) | 2.72 (1.95, 3.79) | < 0.0001 | 2.07 (1.41, 3.03) | 0.0002 |
AJCC 8th ed. stage | |||||
I | 62.01 (52.16, 67.18) | 1.0 (reference) | |||
II | 48.63 (38.74, 54.83) | 1.52 (0.85, 2.73) | 0.1617 | ||
III | 23.57 (20.94, 34.72) | 2.88 (1.66, 4.97) | 0.0002 | ||
Lymph node yield | |||||
< 12 | 67.23 (59.97, 70.52) | 1.0 (reference) | |||
≥ 12 | 59.82 (54.82, 68.51) | 1.12 (0.82, 1.53) | 0.4740 | ||
LVI | |||||
No | 52.37 (49.98, 55.01) | 1.0 (reference) | 1.0 (reference) | ||
Yes | 40.32 (38.92, 45.08) | 2.01 (1.23, 3.29) | 0.0054 | 1.46 (0.86, 2.50) | 0.1628 |
PNI | |||||
No | 66.69 (60.83, 72.90) | 1.0 (reference) | |||
Yes | 62.75 (59.38, 68.47) | 1.57 (0.90, 2.73) | 0.1121 | ||
TD | |||||
No | 59.21 (55.34, 62.07) | 1.0 (reference) | 1.0 (reference) | ||
Yes | 49.10 (45.12, 52.55) | 1.46 (1.05, 2.04) | 0.0248 | 1.10 (0.74, 1.65) | 0.6262 |
Adjuvant chemotherapy | |||||
No | 63.17 (57.82, 65.10) | 1.0 (reference) | |||
Yes | 55.86 (50.16, 60.04) | 0.99 (0.74, 1.32) | 0.9380 | ||
Chemotherapy regimen | |||||
5-FU/capecitabine | 66.81 (61.90, 67.21) | 1.0 (reference) | |||
CAPOX/XELOX | 60.52 (58.42, 62.00) | 1.62 (0.87, 3.03) | 0.1284 | ||
FOLFOX | 53.26 (50.86, 65.33) | 1.49 (0.82, 2.72) | 0.1931 | ||
Other | 57.82 (51.78, 64.93) | 1.80 (0.81, 4.01) | 0.1510 | ||
Chemotherapy cycle | |||||
< 6 | 51.42 (48.26, 58.95) | 1.0 (reference) | |||
≥ 6 | 59.71 (54.01, 63.29) | 0.86 (0.64, 1.16) | 0.3113 | ||
Adjuvant radiotherapy | |||||
No | 59.28 (51.90, 62.77) | 1.0 (reference) | |||
Yes | 58.01 (51.00, 58.52) | 0.68 (0.43, 1.07) | 0.0950 | ||
Palliative chemotherapy | |||||
No | 57.02 (49.72, 60.73) | 1.0 (reference) | |||
Yes | 55.88 (50.14, 58.92) | 1.10 (0.84, 1.44) | 0.5048 | ||
Age group | |||||
< 65 | 60.27 (53.93, 64.07) | 1.0 (reference) | |||
≥ 65 | 57.82 (53.87, 62.05) | 0.95 (0.72, 1.26) | 0.7132 | ||
BM group | |||||
< 24 | 56.87 (48.97, 57.65) | 1.0 (reference) | 1.0 (reference) | ||
≥ 24 | 40.67 (31.98, 44.06) | 1.46 (1.12, 1.89) | 0.0046 | 1.12 (0.81, 1.54) | 0.4850 |
Preoperative CEA group | |||||
< 5 | 43.82 (39.92, 52.06) | 1.0 (reference) | 1.0 (reference) | ||
≥ 5 | 46.92 (41.77, 49.27) | 1.44 (1.06, 1.95) | 0.0183 | 1.29 (0.92, 1.80) | 0.1336 |
Preoperative CA19-9 group | |||||
< 37 | 49.82 (45.34, 54.37) | 1.0 (reference) | 1.0 (reference) | ||
≥ 37 | 30.62 (28.54, 42.45) | 1.80 (1.35, 2.40) | < 0.0001 | 1.31 (0.93, 1.85) | 0.1170 |